Follow us on Twitter
twitter icon@FreshPatents


Autoimmune Disorders patents

      

This page is updated frequently with new Autoimmune Disorders-related patent applications.




 Methods and compositions for treating autoimmune and inflammatory conditions patent thumbnailMethods and compositions for treating autoimmune and inflammatory conditions
Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (apc)-targeted antibody operatively linked to il-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders..
Baylor Research Institute


 Dna aptamers specific to cd200r1 and their therapeutic uses patent thumbnailDna aptamers specific to cd200r1 and their therapeutic uses
Disclosed are short dna aptamers that selectively recognize cd200r1, a protein expressed on the surface of myeloid and lymphoid cells that delivers immune inhibitory signals to modulate inflammation when engaged with its ligand, cd200. Also disclosed is the use of said aptamers as therapeutic agents, for the purpose of decreasing inflammatory response; treatment of spinal cord injury; treatment of an immune related disease such as arthritis, allergy, infection; as a course of treatment during or after transplantation; or for treatment of an autoimmune disorders such as systemic lupus erythematosus, parkinson's disease, or multiple sclerosis..
D5pharma Inc.


 Cysteine, n-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions thereof, and methods of use patent thumbnailCysteine, n-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions thereof, and methods of use
Cysteine, n-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions comprising the cysteine, n-acetylcysteine, and penicillamine related compounds, and methods of using cysteine, n-acetylcysteine, and penicillamine related compounds and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including paracetamol overdose, non-alcoholic steatohepatitis, wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial lung disease, asthma, cystic fibrosis, parkinson's disease, and huntington's disease.. .

 Detection of shed cd31, diagnosis of atherothrombosis and autoimmune disorders, and methods for analyzing signaling pathways patent thumbnailDetection of shed cd31, diagnosis of atherothrombosis and autoimmune disorders, and methods for analyzing signaling pathways
The present invention stems from the finding that the extracellular domain of cd31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of cd31. A method for detecting shed cd31 is further disclosed.
Institut National De La Sante Et De La Recherche Medicale (inserm)


 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier patent thumbnailBacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.. .
Synlogic, Inc.


 Amido compounds as roryt modulators and uses thereof patent thumbnailAmido compounds as roryt modulators and uses thereof
And wherein n1, n2, r1a, r1b, r2, r3, r4, r5, and r6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease..

 Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases patent thumbnailInduced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, huntington's disease, epilepsy, multiple sclerosis (ms), lupus, type-1 and type-2 diabetes, maturity onset diabetes of the young (mody), myasthenia gravis (mg), rheumatoid arthritis (ra), graves' disease, guillain-barré syndrome (gbs), metabolic syndrome, muscular dystrophy or duchenne muscular dystrophy (dmd), severe burns, aging, amyotrophic lateral sclerosis (als), friedreich's ataxia, batten disease, alzheimer's disease, optic neuritis, leber's hereditary optic neuropathy (lhon), autism, rett syndrome, batten disease, angelman's syndrome, leigh disease, fragile-x syndrome, depression, parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous bdnf expression with dnp treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. Dnp was administered to mice daily over a range of doses, and subsequently bdnf expression in the brain showed a dose dependent and non-linear increase in expression..
Mitochon Pharmaceuticals, Inc.


 Human antibodies that bind cd22 and uses thereof patent thumbnailHuman antibodies that bind cd22 and uses thereof
The present disclosure provides isolated monoclonal antibodies that specifically bind to cd22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E. R. Squibb & Sons, L.l.c.


 Fumarate compounds, pharmaceutical compositions thereof, and methods of use patent thumbnailFumarate compounds, pharmaceutical compositions thereof, and methods of use
Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

 Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases patent thumbnailCompositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes..
The Children's Hospital Of Philadelphia


Method of providing monoclonal auto-antibodies with desired specificity

Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human auto-immunosome and corresponding monoclonal antibody reservoir are provided.
Immunoqure Ag

Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides

This document relates to inhibitors of g protein coupled receptor 6 kinase (grk6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.. .
Mayo Foundation For Medical Education And Research

Small molecule inhibitors of g protein coupled receptor 6 kinase polypeptides

This document relates to inhibitors of g protein coupled receptor 6 kinase (grk6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.. .
Mayo Foundation For Medical Education And Research

Aav-based gene therapy for multiple sclerosis

Disclosed are aav viral-based vector compositions useful in delivering a variety of nucleic acid segments, including those encoding therapeutic polypeptides to selected mammalian host cells for use in therapeutic autoimmune modalities, including, for example, the in vivo induction of immunological tolerance via a liver-directed aav-based gene therapeutic regimen for treating and/or ameliorating autoimmune disorders such as multiple sclerosis.. .
University Of Florida Research Foundation, Inc

Treatment of autoimmune disorders and infections using antagonists of sgk1 activity

The present invention provides novel methods for treating th2-mediated immune disorders and enhancing th1-mediated immune responses in a subject comprising administering to the subject, a pharmaceutical composition comprising a serum-glucocorticoid regulated kinase 1 (sgk1) inhibitor and a pharmaceutically acceptable carrier. Methods for treating a wide range of autoimmune diseases are also taught.
The Johns Hopkins University

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Processes and intermediates for making a jak inhibitor

This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of janus kinases (jak) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.. .
Incyte Holdings Corporation

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Interferon receptor 1 antibodies and their uses

The present invention provides isolated human monoclonal antibodies that bind to ifnar-1 and that are capable of inhibiting the biological activity of type i interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided.
E. R. Squibb & Sons, L.l.c.

Inhibition of isoprenoid biosynthetic pathways to treat autoimmune disorders

The invention provides methods and pharmaceutical compositions that can treat autoimmune disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms.

Method for diagnosing, quantifying, treating, monitoring or evaluating conditions, diseases or disorders associated with human papilloma virus (hpv) infection

A method of diagnosing, quantifying, treating, monitoring or evaluating a condition in a subject is provided. The method comprises obtaining a sample from the subject, detecting and determining the presence or quantity of one or more than one human papilloma virus (hpv) in the sample, wherein the presence or quantity of the one or more than one hpv is indicative of the presence of the condition in the subject or an increased likelihood of the subject for developing the condition when compared to a control.

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Eluting matrix and uses thereof

Cxcl12 polypeptide eluting matrices encapsulating at least one cell are described for use in the treatment of autoimmune disorders.. .
The General Hospital Corporation

Activation and expansion of t-cells using an engineered multivalent signaling platform as a research tool

Provided are a system and methods for selectively inducing expansion of a population of t cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of ctls, preferably human ctls.
The Trustees Of The University Of Pennsylvania

Effector-deficient anti-cd32a antibodies

Effector-deficient anti-cd32a monoclonal antibodies are encompassed, as are method and uses for treating cd32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.. .
Adventist Health System/sunbelt Inc.

Processes and intermediates for making a jak inhibitor

This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of janus kinases (jak) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.. .
Incyte Holdings Corporation

Methods of t cell epitope profiling, making t cell compositions, and treating diseases

Disclosed herein is a method of detecting antigen specific t cells in a sample isolated from a subject and mapping immunostimulatory epitopes of the antigen. Such methods may be used in methods of making antigen specific t cell compositions, e.g., for the treatment of diseases such as cancer, infectious diseases and autoimmune disorders..
Opexa Therapeutics, Inc.

Apoptosis signal-regulating kinase inhibitors

The present application relates to compounds having the inhibitory activity to apoptosis signal-regulating kinase (ask1), thus are thus useful in treating ask1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, copd, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases.. .
Gilead Sciences, Inc.

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosus

The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase a2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus..
The Regents Of The University Of Michigan

Polypeptides and uses thereof for treatment of autoimmune disorders and infection

This invention relates to c1orf32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use thereof for treatment of immune related disorders and infections.. .
Compugen Ltd.

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Type i interferon mimetics as therapeutics for cancer, viral infections, and other diseases

The subject invention pertains to agonist peptides of type i interferons and methods of using the peptides. These peptides are based on the amino acid sequence of the c-terminus region of the type i ifn molecules and are capable of binding to the cytoplasmic domain of type i ifn receptors.
University Of Florida Research Foundation, Inc.

Bipyrazole derivatives as jak inhibitors

Or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of janus kinase (jak) and are useful in the treatment of diseases related to the activity of jak including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.. .

Ibrutinib combination therapy

Combinations of bruton's tyrosine kinase (btk) inhibitors, e.g., 1-((r)-3-(4-amino-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with a second anticancer agent are provided. Also provided are methods of treating cancers, and autoimmune disorders by administering combinations of bruton's tyrosine kinase (btk) inhibitors, e.g., 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and second anticancer agents..
Janssen Pharmaceutica Nv

New 1-(4-pyrimidinyl)-1h-pyrrolo[3,2-c]pyridine derivatives as nik inhibitors

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutica Nv

Compositions and methods of use of phorbol esters

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease.
Biosuccess Biotech Co. Ltd.

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Novel amino pyrimidine derivatives

The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with bruton's tyrosine kinase (btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (copd), transplant rejection, cancers e.g.
Novartis Ag

New 3-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-c]pyridine derivatives as nik inhibitors

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutica Nv

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Fully human antibodies to btla

The present invention relates to binding compounds specific for btla and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human btla and modulate its activity in cancer, inflammatory, and autoimmune disorders..
E.r. Squibb & Sons, L.l.c.

Fc receptor binding proteins

This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.

Fc receptor binding proteins

This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.

Fc receptor binding proteins

This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.

Fc receptor binding proteins

This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.

Fc receptor binding proteins

This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.



Autoimmune Disorders topics:
  • Immune Disorder
  • Autoimmune
  • Autoimmune Disorder
  • Autoimmune Disorders
  • Inflammation
  • Vascular Diseases
  • Vascular Disease
  • Cardiovascular Disease
  • Cardiovascular
  • Atherosclerosis
  • Multiple Sclerosis
  • Antibodies
  • Monoclonal
  • Transplant
  • Immune Disease


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Autoimmune Disorders for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Disorders with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.9505

    file didn't exist3077

    479197 - 0 - 55